{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:16:09Z","timestamp":1790392569354,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","award":["FFC#5\/2020"],"award-info":[{"award-number":["FFC#5\/2020"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022FRSS2H"],"award-info":[{"award-number":["2022FRSS2H"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Lab","doi-asserted-by":"publisher","award":["Assael08A0"],"award-info":[{"award-number":["Assael08A0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2025.02.008","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T07:26:25Z","timestamp":1739949985000},"page":"552-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers"],"prefix":"10.1016","volume":"24","author":[{"given":"Jessica","family":"Conti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6663-8918","authenticated-orcid":false,"given":"Dora","family":"Angyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Kleinfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Valeria","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Calicchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Farinazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rodella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Massella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Frulloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anny","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7727-4638","authenticated-orcid":false,"given":"Tessa A.","family":"Groeneweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-188X","authenticated-orcid":false,"given":"Marcel J.C.","family":"Bijvelds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-1595","authenticated-orcid":false,"given":"Paola","family":"Melotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2739-4014","authenticated-orcid":false,"given":"Claudio","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2025.02.008_bib0001","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2025.02.008_bib0002","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1084\/jem.20120562","article-title":"Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype","volume":"209","author":"Gustafsson","year":"2012","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.02.008_bib0003","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI83922","article-title":"Acidic pH increases airway surface liquid viscosity in cystic fibrosis","volume":"126","author":"Tang","year":"2016","journal-title":"J Clin Invest"},{"issue":"10212","key":"10.1016\/j.jcf.2025.02.008_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2025.02.008_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.02.008_bib0006","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cell.2019.12.032","article-title":"A therapy for most with cystic fibrosis","volume":"180","author":"Bear","year":"2020","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.jcf.2025.02.008_bib0007","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jcf.2025.02.008_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"Chowdhury BA. The U.S. Food and Drug Administration's experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.02.008_bib0009","unstructured":"FDA. Highlights of prescribing information. https:\/\/www.accessdatafdagov\/drugsatfda_docs\/label\/2023\/217660s000lbl.pdf. 04\/2023."},{"issue":"4","key":"10.1016\/j.jcf.2025.02.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.02.008_bib0011","doi-asserted-by":"crossref","unstructured":"Amatngalim GD, Rodenburg LW, Aalbers BL, Raeven HH, Aarts EM, Sarhane D, et al. Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia. Life Sci Alliance. 2022;5(12):e202101320.","DOI":"10.26508\/lsa.202101320"},{"key":"10.1016\/j.jcf.2025.02.008_bib0012","doi-asserted-by":"crossref","unstructured":"Aalbers BL, Brunsveld JE, van der Ent CK, van den Eijnden JC, Beekman JM, Heijerman HGM. Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype. J Cyst Fibros. 2022;21(2):254\u20137.","DOI":"10.1016\/j.jcf.2022.01.008"},{"issue":"12","key":"10.1016\/j.jcf.2025.02.008_bib0013","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.3390\/ijms241210358","article-title":"Theratyping of the rare CFTR genotype A559T in rectal organoids and nasal cells reveals a relevant response to elexacaftor (VX-445) and tezacaftor (VX-661) combination","volume":"24","author":"Kleinfelder","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.02.008_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914539","article-title":"Function restoration upon Elexacaftor\/Tezacaftor\/Ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jcf.2025.02.008_bib0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/jpm12040632","article-title":"Theratyping of the rare CFTR variants E193K and R334W in rectal organoid-derived epithelial monolayers","volume":"12","author":"Ciciriello","year":"2022","journal-title":"J Pers Med"},{"issue":"11","key":"10.1016\/j.jcf.2025.02.008_bib0016","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1164\/rccm.202004-1200LE","article-title":"Comparison of organoid swelling and in vivo biomarkers of CFTR function to determine effects of lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation","volume":"202","author":"Graeber","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcf.2025.02.008_bib0017","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jcf.2025.02.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur Respir J"},{"issue":"19","key":"10.1016\/j.jcf.2025.02.008_bib0019","doi-asserted-by":"crossref","first-page":"14539","DOI":"10.3390\/ijms241914539","article-title":"CFTR function restoration upon Elexacaftor\/Tezacaftor\/Ivacaftor treatment in patient-derived intestinal organoids with rare CFTR genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.02.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","author":"Bihler","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.02.008_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.02.008_bib0022","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jcf.2021.12.006","article-title":"Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers","volume":"21","author":"Bijvelds","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2025.02.008_bib0023","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S1569-1993(11)60009-X","article-title":"New clinical diagnostic procedures for cystic fibrosis in Europe","volume":"10","author":"De Boeck","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.02.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004376","article-title":"Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis","volume":"10","author":"LaRusch","year":"2014","journal-title":"PLoS Genet"},{"issue":"5","key":"10.1016\/j.jcf.2025.02.008_bib0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jcf.2019.01.012","article-title":"Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability","volume":"18","author":"Ferrera","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.02.008_bib0026","article-title":"Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test","volume":"7","author":"Minso","year":"2020","journal-title":"BMJ Open Respir Res"},{"issue":"6","key":"10.1016\/j.jcf.2025.02.008_bib0027","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jcf.2022.09.005","article-title":"ECFS standards of care on CFTR-related disorders: diagnostic criteria of CFTR dysfunction","volume":"21","author":"Sermet-Gaudelus","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.02.008_bib0028","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcf.2018.12.011","article-title":"Predictive factors for lumacaftor\/ivacaftor clinical response","volume":"18","author":"Masson","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.02.008_bib0029","doi-asserted-by":"crossref","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant CFTR","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.jcf.2025.02.008_bib0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","article-title":"DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers","volume":"23","author":"Rowe","year":"2010","journal-title":"Pulm Pharmacol Ther"}],"updated-by":[{"DOI":"10.1016\/j.jcf.2025.02.018","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:09:58Z","timestamp":1762553398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199325000591"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.02.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}